Daniel Y. Sze, MD, PhD (he/him/his)

Professor, Editor in Chief
Stanford University; Journal of Vascular and Interventional Radiology

Presentation(s):

• Extreme IR: The Sirens Are Calling!

  Saturday, March 4, 2023
  1:00 PM – 5:00 PM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)

• Global IR Research - How to get started

  Sunday, March 5, 2023
  8:42 AM – 9:17 AM

  Disclosure information not submitted.

• Cases my fellow screwed up

  Sunday, March 5, 2023
  2:00 PM – 2:15 PM

  Disclosure information not submitted.

• Comparison of 90Y Radioembolization Outcomes for Hepatocellular Carcinoma (HCC) in TACE-refractory (T-REF) vs Treatment Naïve (TN) Patients in the RESiN Registry (NCT: 02685631)

  Sunday, March 5, 2023
  3:45 PM – 3:54 PM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)

• Progression and Survival Outcomes of Hepatocellular Carcinoma (HCC) Patients within Milan Criteria Following Y90 Radioembolization Using the Radiation-Emitting SIR-Spheres in Non-Resectable Tumor (RESiN) Registry NCT 02685631

  Sunday, March 5, 2023
  3:54 PM – 4:03 PM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)

• JVIR Editors' Workshop S

  Sunday, March 5, 2023
  5:00 PM – 6:00 PM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)

• Comparing Survival Outcomes and Toxicities of Y90 Radioembolization of Colorectal Cancer Metastatic to the Liver Between Patients Older and Younger than 70: Analysis from the RESiN Registry (NCT02685631)

  Monday, March 6, 2023
  4:12 PM – 4:21 PM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)

• JVIR Editors' Workshop T

  Tuesday, March 7, 2023
  7:00 AM – 8:00 AM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)

• Film Panel Plenary Session and JVIR Awards recognition

  Tuesday, March 7, 2023
  10:30 AM – 12:00 PM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)

• We are IR: Representation & Mentorship in IR

  Tuesday, March 7, 2023
  5:00 PM – 6:00 PM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)

• Selective Hepatic Vein Sampling for Enriched Circulating Tumor Cell Collection in Patients with Liver Dominant Malignancy—Preliminary Results

  Wednesday, March 8, 2023
  3:27 PM – 3:36 PM

  Disclosure(s): Artio Medical: Consultant (Terminated, January 1, 2021); Astra Zeneca: Consultant (Terminated, January 1, 2021); Bayer: Consultant (Terminated, January 1, 2021); BlackSwan Vascular: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Boston Scientific / Biocompatibles BTG: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Bristol Myers Squibb: Consultant (Terminated, January 1, 2021); Eisai: Consultant (Terminated, January 1, 2021); FluidX: Consultant (Terminated, January 1, 2021); Guerbet: Consultant (Terminated, January 1, 2021); Koli Medical, Inc.: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); RadiAction Medical: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Sirtex Medical: Consultant (Terminated, January 1, 2021), Contracted Research (Terminated, January 1, 2021); Terumo: Consultant (Terminated, January 1, 2021); Trisalus Life Sciences: Consultant (Terminated, January 1, 2021), Ownership Interest (Terminated, January 1, 2021); Varian: Consultant (Terminated, January 1, 2021); W. L. Gore: Consultant (Terminated, January 1, 2021)